Preablative serum thyroglobulin as predictor of disease-free survival in differentiated thyroid cancer Importancia de la tiroglobulina sérica preablativa en la predicción de sobrevida libre de enfermedad en cancer diferenciado de tiroides
Author
dc.contributor.author
Díaz, René E.
Author
dc.contributor.author
Véliz, Jesús
Author
dc.contributor.author
Wohllk, Nelson
Admission date
dc.date.accessioned
2019-03-15T16:06:11Z
Available date
dc.date.available
2019-03-15T16:06:11Z
Publication date
dc.date.issued
2013
Cita de ítem
dc.identifier.citation
Revista Medica de Chile, Volumen 141, Issue 12, 2018, Pages 1506-1511
Identifier
dc.identifier.issn
07176163
Identifier
dc.identifier.issn
00349887
Identifier
dc.identifier.other
10.4067/S0034-98872013001200002
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/166136
Abstract
dc.description.abstract
Background: Serum thyroglobulin (sTg) is an excellent marker of persistence or recurrence of disease in differentiated thyroid cancer (DTC), however its role as prognostic factor has not been fully established. Aim: To assess the value of the prea-blative thyroglobulin (pTg) as predictor of disease-free survival in DTC. Patients and Methods: Retrospective study of 104 patients with low and intermediate risk DTC subjected to total thyroidectomy and 131iodine ablation. TSH, pTg and thyro-globulin antibodies (AbTg) were determined by chemiluminescence. Patients with distant metastases or presence of AbTg were excluded. Results were analyzed using receiving operating characteristic (ROC) curves. Results: During the 40 ± 29 months of follow-up (range 6-132), 14 of 104 (13%) patients had recurrence of disease. pTg was an independent indicator to predict disease-free survival. Using a pTg cutoff of < 10 ng/ml the negative predictive value was 99%, sensitivity 93%, specificity 82%, positive li
Preablative serum thyroglobulin as predictor of disease-free survival in differentiated thyroid cancer Importancia de la tiroglobulina sérica preablativa en la predicción de sobrevida libre de enfermedad en cancer diferenciado de tiroides